An evaluation of anifrolumab for use in adults with systemic lupus erythematosus

References

• Catalina MD, Owen KA, Labonte AC, et al. The pathogenesis of systemic lupus erythematosus: harnessing big data to understand the molecular basis of lupus. J Autoimmun. 2020;110:102359. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Contin-Bordes C, Lazaro E, Pellegrin JL, et al. Systemic lupus erythematosus: from pathophysiology to treatment. Rev Med Interne. 2009;30(12):H9–13. [published Online First: Epub Date]|.
   PubMedGoogle Scholar
• Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332–2343. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Gurevitz SL, Snyder JA, Wessel EK, et al. Systemic lupus erythematosus: a review of the disease and treatment options. Consult Pharm. 2013;28(2):110–121. [published Online First: Epub Date]|.
   PubMedGoogle Scholar
• Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015;75(8):835–846. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Metry AM, Al Salmi I, Al Balushi F, et al. Systemic lupus erythematosus: symptoms and signs at initial presentations. Antiinflamm Antiallergy Agents Med Chem. 2019;18(2):142–150. [published Online First: Epub Date]|.
   PubMedGoogle Scholar
• Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(Suppl 4):S4. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Seridi L, Cesaroni M, Orillion A, et al. Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition. Lupus. 2021;30(5):795–806. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Mathias LM, Stohl W. Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opin Ther Targets. 2020;24(12):1283–1302. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Herrmann M, Muñoz LE. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol. 2016;7:35. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the united states: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries. Arthritis Rheumatol. 2021;73(6):991–996. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Nusbaum JS, Mirza I, Shum J, et al. Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis. Mayo Clin Proc. 2020;95(2):384–394. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Singh RR, Yen EY. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus. 2018;27(10):1577–1581. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Yen EY, Singh RR. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015. Arthritis Rheumatol. 2018;70(8):1251–1255. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Goulielmos GN, Zervou MI, Vazgiourakis VM, et al. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene. 2018;668:59–72. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301(1):5–8. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Anderson E, Furie R. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations. Immunotherapy. 2020;12(5):275–286. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012;64(11):3666–3676. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196–202. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65(4):1011–1021. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol. 2021;31(1):1–12. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16(1):R57. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Tummala R, Rouse T, Berglind A, et al. Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018;5(1):e000252. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, et al.Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376–386. [published Online First: Epub Date].
   PubMed Web of Science ®Google Scholar
• Chatham WW, Furie R, Saxena A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase ii open-label extension study. Arthritis Rheumatol. 2021;73(5):816–825. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Okada M, et al. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheumatol. 2020;30(1):101–108. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Bruce IN, Nami A, Schwetje E, et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Rheumatol. 2021;3:e101–e10.
   Google Scholar
• Jayne D, Rovin B, Mysler E, et al. pos0690 randomized, controlled, phase 2 trial of type 1 ifn inhibitor anifrolumab in patients with active proliferative lupus nephritis: BMJ Publishing Group Ltd, 2021.
   Google Scholar
• Furie RA, Morand EF, Bruce IN, et al., Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208–e19.
   PubMedGoogle Scholar
• Morand EF, Furie R, Tanaka Y, et al.Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2019;382(3):211–221. [published Online First: Epub Date].
   PubMed Web of Science ®Google Scholar